Cardio-Oncology
Living Guideline
This site offers two resources for clinicians: a continuously updated cardio-oncology guideline — every 2022 ESC recommendation reviewed against new 2023–2026 evidence — and an integrated prostate-cancer cardiovascular risk calculator for rapid triage and PREVENT-based 10-year risk scoring.
Two Clinical Resources, One Goal
Evidence-Based
Every update is grounded in peer-reviewed publications, RCTs, and society consensus statements.
Continuously Updated
Sections are revised as new evidence emerges. Version dates are displayed for full transparency.
Feedback-Driven
Clinicians can submit corrections, new references, or suggested changes directly through the site.
Browse Sections
Recent Updates
September 2026
§7–7.5
Section 7 added: end-of-therapy assessment, medication withdrawal and rehabilitation
First-year surveillance guidance with dynamic risk re-stratification (RE-ACT), the randomized HER-SAFE withdrawal trial for recovered anti-HER2 CTRCD, the CORE cardio-oncology rehabilitation RCT, and quantitative cardiorespiratory-fitness evidence.
September 2026
§6.7–6.10.2
Bleeding, PAD, pulmonary hypertension and pericardial disease pages added
PRECISE-DAPT Cancer and ONCO-DOAC BLEED bleeding scores, the no-benefit TXA trials (A-TREAT/TREATT), the 2024 ACC/AHA PAD guideline, comparative dasatinib PAH risk, the 2025 ESC pericarditis guideline, and the randomized PMAP balloon pericardiotomy trial.
September 2026
§6.6–6.6.4.2
Thrombosis and anticoagulation pages added
Updated VTE/ATE incidence estimates, dynamic thrombotic-risk assessment including CDK4/6 inhibitors, reduced-dose extended apixaban (API-CAT/EVE), the CANVAS randomized trial, and upgraded ambulatory and postoperative prophylaxis recommendations.
September 2026
§6.4.2 & 6.4.3, 6.5
QT, bradyarrhythmia and hypertension pages added
CDK4/6 inhibitor QTc meta-analysis, delayed osimertinib QT toxicity, ICI conduction disease as myocarditis, the 2024 ESC hypertension targets, and the randomized EAQ191 intensive blood-pressure trial in VEGFR TKI patients.
September 2026
§6.2–6.4.1
Coronary disease, valvular disease and arrhythmia management pages added
Cancer-specific hs-cTn performance, the ONCO-ACS risk score, individualized DAPT, the 2025 ESC/EACTS valvular heart disease guideline, and the AF-CARE/CHA2DS2-VA framework.